Michaël Pollak

65.2k total citations · 16 hit papers
599 papers, 46.8k citations indexed

About

Michaël Pollak is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Michaël Pollak has authored 599 papers receiving a total of 46.8k indexed citations (citations by other indexed papers that have themselves been cited), including 304 papers in Molecular Biology, 252 papers in Endocrinology, Diabetes and Metabolism and 247 papers in Oncology. Recurrent topics in Michaël Pollak's work include Growth Hormone and Insulin-like Growth Factors (232 papers), Metabolism, Diabetes, and Cancer (228 papers) and Cancer Risks and Factors (120 papers). Michaël Pollak is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (232 papers), Metabolism, Diabetes, and Cancer (228 papers) and Cancer Risks and Factors (120 papers). Michaël Pollak collaborates with scholars based in Canada, United States and United Kingdom. Michaël Pollak's co-authors include Susan E. Hankinson, Edward L. Giovannucci, Mahvash Zakikhani, Nahum Sonenberg, Eva Schernhammer, Hung Huynh, Ryan J.O. Dowling, Meir J. Stampfer, June M. Chan and Jing Ma and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Michaël Pollak

577 papers receiving 45.5k citations

Hit Papers

Diabetes and Cancer 1998 2026 2007 2016 2010 1998 2008 1998 2004 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Diabetes and Cancer
    2010 1.8k citations Edward L. Giovannucci, David M. Harlan et al. Diabetes Care profile →
  2. Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
    1998 1.6k citations Edward L. Giovannucci, Michaël Pollak et al. profile →
  3. Insulin and insulin-like growth factor signalling in neoplasia
    2008 1.6k citations Michaël Pollak Nature reviews. Cancer profile →
  4. Circulating concentrations of insulin-like growth factor I and risk of breast cancer
    1998 1.5k citations Graham A. Colditz, Michaël Pollak et al. profile →
  5. Insulin-like growth factors and neoplasia
    2004 1.2k citations Michaël Pollak et al. Nature reviews. Cancer profile →
  6. Metformin: From Mechanisms of Action to Therapies
    2014 1.1k citations Michaël Pollak, Benoı̂t Viollet et al. profile →
  7. Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3
    1999 912 citations Michaël Pollak et al. profile →
  8. Metformin Is an AMP Kinase–Dependent Growth Inhibitor for Breast Cancer Cells
    2006 881 citations Nahum Sonenberg, Michaël Pollak et al. Cancer Research profile →
  9. The insulin and insulin-like growth factor receptor family in neoplasia: an update
    2012 868 citations Michaël Pollak Nature reviews. Cancer profile →
  10. Diabetes and Cancer: A Consensus Report
    2010 819 citations Edward L. Giovannucci, David M. Harlan et al. profile →
  11. Metformin Inhibits Mammalian Target of Rapamycin–Dependent Translation Initiation in Breast Cancer Cells
    2007 770 citations Michaël Pollak, Nahum Sonenberg et al. Cancer Research profile →
  12. Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
    2000 738 citations Michaël Pollak et al. profile →
  13. Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
    2001 699 citations Xiaolin Zi, Michaël Pollak et al. profile →
  14. mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation
    2013 614 citations Daina Avizonis, Michaël Pollak et al. profile →
  15. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria
    2014 497 citations Michaël Pollak et al. profile →
  16. Metformin inhibits the senescence‐associated secretory phenotype by interfering with IKK/NF‐κB activation
    2013 486 citations Olga Moiseeva, Xavier Deschênes‐Simard et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michaël Pollak Canada 103 26.6k 15.9k 15.3k 11.6k 5.2k 599 46.8k
Charis Eng United States 106 24.0k 0.9× 9.8k 0.6× 8.4k 0.5× 8.3k 0.7× 4.1k 0.8× 647 44.8k
David W. Russell United States 126 29.5k 1.1× 8.0k 0.5× 7.1k 0.5× 4.7k 0.4× 2.3k 0.4× 542 52.6k
Eleftherios P. Diamandis Canada 103 17.2k 0.6× 9.7k 0.6× 2.5k 0.2× 6.2k 0.5× 5.8k 1.1× 940 44.5k
Howard I. Scher United States 125 18.2k 0.7× 22.8k 1.4× 5.4k 0.4× 13.7k 1.2× 34.1k 6.5× 804 63.5k
Stephen B. Baylin United States 131 60.4k 2.3× 16.0k 1.0× 2.2k 0.1× 13.8k 1.2× 6.5k 1.2× 444 77.0k
Ronald A. DePinho United States 149 56.0k 2.1× 23.0k 1.4× 2.2k 0.1× 13.7k 1.2× 4.4k 0.8× 417 86.1k
Anthony Howell United Kingdom 112 12.4k 0.5× 21.3k 1.3× 2.0k 0.1× 15.1k 1.3× 6.6k 1.3× 684 42.9k
Charles L. Sawyers United States 99 24.8k 0.9× 12.3k 0.8× 3.1k 0.2× 9.3k 0.8× 15.9k 3.1× 266 53.4k
Kari Hemminki Sweden 86 12.3k 0.5× 10.1k 0.6× 1.4k 0.1× 9.0k 0.8× 4.3k 0.8× 1.0k 35.2k
Razelle Kurzrock United States 119 21.0k 0.8× 24.9k 1.6× 1.7k 0.1× 13.3k 1.1× 12.3k 2.4× 1.2k 60.4k

Countries citing papers authored by Michaël Pollak

Since Specialization
Citations

This map shows the geographic impact of Michaël Pollak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michaël Pollak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michaël Pollak more than expected).

Fields of papers citing papers by Michaël Pollak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michaël Pollak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michaël Pollak. The network helps show where Michaël Pollak may publish in the future.

Co-authorship network of co-authors of Michaël Pollak

This figure shows the co-authorship network connecting the top 25 collaborators of Michaël Pollak. A scholar is included among the top collaborators of Michaël Pollak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michaël Pollak. Michaël Pollak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Anderson, Kenneth C., Lewis C. Cantley, Riccardo Dalla‐Favera, et al.. (2022). The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Discovery. 12(11). 2475–2481.
2.
Pollak, Michaël, et al.. (2022). Total Wrist Arthroplasty for Posttraumatic Wrist Osteoarthritis: A Cohort Study Comparing Three Indications. Life. 12(5). 617–617. 2 indexed citations
3.
Liu, Zhongbo, Noriko Yokoyama, Christopher Blair, et al.. (2016). High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum. Molecular Cancer Therapeutics. 15(3). 430–438. 13 indexed citations
4.
Hofmann, Jonathan N., Brenda M. Birmann, Lauren R. Teras, et al.. (2016). Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. Cancer Research. 76(7). 1935–1941. 27 indexed citations
5.
Iyengar, Neil M., Xi Kathy Zhou, Ayca Gucalp, et al.. (2015). Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. Clinical Cancer Research. 22(9). 2283–2289. 162 indexed citations
6.
Fendt, Sarah‐Maria, Eric L. Bell, Mark A. Keibler, et al.. (2013). Metformin Decreases Glucose Oxidation and Increases the Dependency of Prostate Cancer Cells on Reductive Glutamine Metabolism. Cancer Research. 73(14). 4429–4438. 7 indexed citations
7.
Friedbichler, Katrin, Marco H. Hofmann, Elínborg Ostermann, et al.. (2013). Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin. Molecular Cancer Therapeutics. 13(2). 399–409. 73 indexed citations
8.
Li, Rui, Alexandre Montpetit, Marylène Rousseau, et al.. (2013). Somatic point mutations occurring early in development: a monozygotic twin study. Journal of Medical Genetics. 51(1). 28–34. 53 indexed citations
9.
Algire, Carolyn, Olga Moiseeva, Xavier Deschênes‐Simard, et al.. (2012). Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage. Cancer Prevention Research. 5(4). 536–543. 288 indexed citations
10.
Lubik, Amy A., Jennifer H. Gunter, Stephen C. Hendy, et al.. (2011). Insulin Increases De Novo Steroidogenesis in Prostate Cancer Cells. Cancer Research. 71(17). 5754–5764. 91 indexed citations
11.
Giovannucci, Edward L., David M. Harlan, Michael C. Archer, et al.. (2010). Diabetes and Cancer. Diabetes Care. 33(7). 1674–1685. 1753 indexed citations breakdown →
12.
Pollak, Michaël. (2010). Metformin and Other Biguanides in Oncology: Advancing the Research Agenda. Cancer Prevention Research. 3(9). 1060–1065. 182 indexed citations
13.
Furic, Luc, Liwei Rong, Ola Larsson, et al.. (2010). eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proceedings of the National Academy of Sciences. 107(32). 14134–14139. 398 indexed citations
14.
Mavropoulos, John C., W. Cooper Buschemeyer, Alok K. Tewari, et al.. (2009). The Effects of Varying Dietary Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer Xenograft Model. Cancer Prevention Research. 2(6). 557–565. 86 indexed citations
15.
Pollak, Michaël. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nature reviews. Cancer. 8(12). 915–928. 1604 indexed citations breakdown →
16.
Law, Jennifer, Golareh Habibi, Kaiji Hu, et al.. (2008). Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival. Cancer Research. 68(24). 10238–10246. 339 indexed citations
17.
Raina, Komal, Marie‐José Blouin, Rana P. Singh, et al.. (2007). Dietary Feeding of Silibinin Inhibits Prostate Tumor Growth and Progression in Transgenic Adenocarcinoma of the Mouse Prostate Model. Cancer Research. 67(22). 11083–11091. 65 indexed citations
18.
Lu, Yuhong, Xiaolin Zi, & Michaël Pollak. (2003). Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. International Journal of Cancer. 108(3). 334–341. 159 indexed citations
19.
Toppmeyer, Deborah, Andrew D. Seidman, Michaël Pollak, et al.. (2002). Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.. PubMed. 8(3). 670–8. 61 indexed citations
20.
Spitz, Margaret R., Matt J. Barnett, Gary E. Goodman, et al.. (2002). Serum Insulin-like Growth Factor (IGF) and IGF-binding Protein Levels and Risk of Lung Cancer. Cancer Epidemiology and Prevention Biomarkers. 11(11). 1413–1418. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charis Eng Breakdown of academic impact, for papers by David W. Russell Breakdown of academic impact, for papers by Eleftherios P. Diamandis Breakdown of academic impact, for papers by Howard I. Scher Breakdown of academic impact, for papers by Stephen B. Baylin Breakdown of academic impact, for papers by Ronald A. DePinho Breakdown of academic impact, for papers by Anthony Howell Breakdown of academic impact, for papers by Charles L. Sawyers Breakdown of academic impact, for papers by Kari Hemminki Breakdown of academic impact, for papers by Razelle Kurzrock
Rankless by CCL
2026